TY - JOUR
T1 - n-3 PUFAs improve erythrocyte fatty acid profile in patients with small AAA: a randomized controlled trial
AU - Meital, Lara T.
AU - Windsor, Mark T.
AU - Ramirez Jewell, Rebecca M. L.
AU - Young, Peter
AU - Schulze, Karl
AU - Magee, Rebecca
AU - O’Donnell, Jill
AU - Jha, Pankaj
AU - Perissiou, Maria
AU - Golledge, Jonathan
AU - Bailey, Tom G.
AU - Brooks, Peter
AU - Askew, Christopher D.
AU - Russell, Fraser D.
PY - 2019/6/1
Y1 - 2019/6/1
N2 - Abdominal aortic aneurysm (AAA) is an important cause of death in older adults, which has no current drug therapy. Inflammation and abnormal redox status are believed to be key pathogenic mechanisms for AAA. In light of evidence correlating inflammation with aberrant fatty acid profiles, this study compared erythrocyte fatty acid content in 43 AAA patients (diameter 3.0–4.5 cm) and 52 healthy controls. In addition, the effect of omega-3 PUFA (n-3 PUFA) supplementation on erythrocyte fatty acid content was examined in a cohort of 30 AAA patients as part of a 12 week randomized placebo-controlled clinical trial. Blood analyses identified associations between AAA and decreased linoleic acid (LA), and AAA and increased Δ6-desaturase activity and biosynthesis of arachidonic acid (AA) from LA. Omega-3 PUFA supplementation (1.5 g DHA + 0.3 g EPA/day) decreased red blood cell distribution width (14.8 ± 0.4% to 13.8 ± 0.2%; P = 0.003) and levels of pro-inflammatory n-6 PUFAs (AA, 12.46 ± 0.23% to 10.14 ± 0.3%, P < 0.001; adrenic acid, 2.12 ± 0.13% to 1.23 ± 0.09%; P < 0.001). In addition, Δ-4 desaturase activity increased (DHA/docosapentaenoic acid ratio, 1.85 ± 0.14 to 3.93 ± 0.17; P < 0.001) and elongase 2/5 activity decreased (adrenic acid/AA ratio, 0.17 ± 0.01 to 0.12 ± 0.01; P < 0.01) following supplementation. The findings suggest that n-3 PUFAs improve fatty acid profiles and ameliorate factors associated with inflammation in AAA patients.
AB - Abdominal aortic aneurysm (AAA) is an important cause of death in older adults, which has no current drug therapy. Inflammation and abnormal redox status are believed to be key pathogenic mechanisms for AAA. In light of evidence correlating inflammation with aberrant fatty acid profiles, this study compared erythrocyte fatty acid content in 43 AAA patients (diameter 3.0–4.5 cm) and 52 healthy controls. In addition, the effect of omega-3 PUFA (n-3 PUFA) supplementation on erythrocyte fatty acid content was examined in a cohort of 30 AAA patients as part of a 12 week randomized placebo-controlled clinical trial. Blood analyses identified associations between AAA and decreased linoleic acid (LA), and AAA and increased Δ6-desaturase activity and biosynthesis of arachidonic acid (AA) from LA. Omega-3 PUFA supplementation (1.5 g DHA + 0.3 g EPA/day) decreased red blood cell distribution width (14.8 ± 0.4% to 13.8 ± 0.2%; P = 0.003) and levels of pro-inflammatory n-6 PUFAs (AA, 12.46 ± 0.23% to 10.14 ± 0.3%, P < 0.001; adrenic acid, 2.12 ± 0.13% to 1.23 ± 0.09%; P < 0.001). In addition, Δ-4 desaturase activity increased (DHA/docosapentaenoic acid ratio, 1.85 ± 0.14 to 3.93 ± 0.17; P < 0.001) and elongase 2/5 activity decreased (adrenic acid/AA ratio, 0.17 ± 0.01 to 0.12 ± 0.01; P < 0.01) following supplementation. The findings suggest that n-3 PUFAs improve fatty acid profiles and ameliorate factors associated with inflammation in AAA patients.
KW - omega-3 fatty acids
KW - antioxidants
KW - clinical studies
KW - diet and dietary lipids
KW - diet effects/lipid metabolism
KW - abdominal aortic aneurysms
KW - omega-3 index
KW - polyunsaturated fatty acids
UR - http://research.usc.edu.au/vital/access/manager/Repository/usc:28444?exact=sm_creator%3A%22Perissiou%2C+Maria-Christina%22
UR - http://www.jlr.org/lookup/doi/10.1194/jlr.P093013
U2 - 10.1194/jlr.P093013
DO - 10.1194/jlr.P093013
M3 - Article
SN - 1539-7262
VL - 60
SP - 1154
EP - 1163
JO - Journal of Lipid Research
JF - Journal of Lipid Research
IS - 6
ER -